State-of-the-Art Glycomics Technologies in Glycobiotechnology
Glycosylation affects the properties of biologics; thus regulatory bodies classified it as critical quality attribute and force biopharma industry to capture and control it throughout all phases, from R&D till end of product lifetime. The shift from o
- PDF / 846,090 Bytes
- 33 Pages / 439.37 x 666.142 pts Page_size
- 86 Downloads / 151 Views
State-of-the-Art Glycomics Technologies in Glycobiotechnology Alexander Pralow, Samanta Cajic, Kathirvel Alagesan, Daniel Kolarich, and Erdmann Rapp
Contents 1 Introduction 2 Established Technologies for the Analysis of Glycans in the Biopharmaceutical Industry 2.1 Liquid Chromatography-Based Glycan Analysis 2.2 Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry-Based Glycan Analysis 2.3 Capillary Electrophoresis-Based Glycan Analysis 3 Emerging Technologies for the Analysis of Glycans in the Biopharmaceutical Industry 3.1 Porous Graphitized Carbon Liquid Chromatography Online Coupled to MS for Nand O-Glycomics 3.2 Ion-Mobility Mass Spectrometry-Based Glycan Analysis
A. Pralow and S. Cajic Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany K. Alagesan Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia D. Kolarich Institute for Glycomics, Griffith University, Gold Coast, QLD, Australia ARC Centre of Excellence in Nanoscale Biophotonics, Griffith University, Gold Coast, QLD, Australia E. Rapp (*) Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany glyXera GmbH, Magdeburg, Germany e-mail: [email protected]; [email protected]
A. Pralow et al. 4 Applications in the Biopharmaceutical Industry 4.1 Glycomics of Monoclonal Antibodies 4.2 Glycomics of Pharmaceutically Relevant Glycoproteins Beyond Monoclonal Antibodies 4.3 Glycomics of Vaccine Antigens 5 Conclusion References
Abstract Glycosylation affects the properties of biologics; thus regulatory bodies classified it as critical quality attribute and force biopharma industry to capture and control it throughout all phases, from R&D till end of product lifetime. The shift from originators to biosimilars further increases importance and extent of glycoanalysis, which thus increases the need for technology platforms enabling reliable high-throughput and in-depth glycan analysis. In this chapter, we will first summarize on established glycoanalytical methods based on liquid chromatography focusing on hydrophilic interaction chromatography, capillary electrophoresis focusing on multiplexed capillary gel electrophoresis, and mass spectrometry focusing on matrix-assisted laser desorption; we will then highlight two emerging technologies based on porous graphitized carbon liquid chromatography and on ion-mobility mass spectrometry as both are highly promising tools to deliver an additional level of information for in-depth glycan analysis; additionally we elaborate on the advantages and challenges of different glycoanalytical technologies and their complementarity; finally, we briefly review applications thereof to biopharmaceutical products. This chapter provides an overview of current state-of-the-art analytical approaches for glycan characterization of biopharmaceuticals that can be employed to capture glycoprotein heterogeneity in a biopharmaceutical context.
Int.
Graphical Abstract
RT/MTU
N-/O-Glycans
Glycoproteins (e.g. mAbs, Hormones, Viral Angens)
Measurement
e.g
Data Loading...
